Dow Jones 10543.88 -9.61 6:48 am PST, June 3, 2005  NASDAQ 2095.41 -2.39 For info, visit access.smallcapnetwork.com S & P 500 1204.72 +0..43 Change your subscription status here Russell 2000 625.24 +0.00 VOLUME 05: ISSUE 42  Feature: BioCurex's RECAF Marker - The World is Waiting. For several days in September, in Rhodes Greece, the elite of the oncology community--academia and industry--will gather at the 33rd   congress of the International Society of Oncodevelopmental Biology and Medicine (ISOBM). This prestigious event brings together the best and brightest of the global oncology community and, through several presentations regarding its RECAF? technology, BioCurex will delineate its science (BOCX.PK) to many potential research and licensing partners from around the world. Three members of BioCurex's impressive scientific advisory board, including CEO Ricardo Moro will present (release--with bio's-- below) on topics dealing with the company's proprietary RECAF? marker technology. Other presenters from the Advisory Board will be the highly regarded Dr. Philip Gold--whose work ushered in the modern era of human cancer marker research and diagnostics with his development of the CEA and PSA markers--the most employed cancer markers worldwide.  As well, Dr. Jose Uriel, a distinguished scientist with an impressive research and prolific publishing history will present " The Physiological Role of AFP and its Cell Receptors" (RECAF?). The ISOBM is one of the longest standing and best-reputed forums for cancer markers in the world and it publishes the journal "Tumor Biology". All of these high-level presentations will undoubtedly further educate peers both in academia and industry with the exciting and ongoing developments regarding BioCurex's research, testing, and future initiatives. With this amount of expertise in the same locale, there will likely be many opportunities to expand and expose the benefits of both RECAF? and BioCurex's applications to the attendees. Interestingly, one of the main sponsors of the Congress is Abbott Diagnostics (NYSE: ABT)--a BioCurex licensee. Needless to say, the association between the two companies, we believe, should open significant doors for both; given the potential of RECAF ? technology. Our indicators show that the shares may well be a bit oversold. There have been some violations of the .618 percent retracement level, and we would like to see this level hold. It's no secret that we'd like to see the shares off of the Pink Sheets, and feel that this and some other extraneous factors have worked to moderate the share action. That said, for long-term investors, accumulation at these levels and on dips continues to appear warranted. Let me review for a moment. We've followed this company for 18 months. In that time the price has gone from pennies to multiple dollars back to just above a dollar. The progress in both the research and corporate developments should well be the envy of every other smallcap biotech. The potential of this technology, in our opinion, is beyond amazing. We've said before and say again; BioCurex's technology has the potential to revolutionize the way cancer is detected, treated and managed. At full sail, it could well save millions of lives or, at the very least, vastly improve the survival odds for patients. An investment in BioCurex appears warranted for risk-oriented and, dare I say, prescient investors.   Press Release Source: BioCurex, Inc. Three BioCurex Scientists to Lecture at International Cancer Congress. RICHMOND, British Columbia, June 2, 2004. -- BioCurex Inc. (BOCX.PK - News) announced today that three members of its Scientific Advisory Board have been invited to make oral presentations at the 2005 meeting of the International Society of Oncodevelopmental Biology and Medicine (ISOBM) to be held in September 2005 in Rhodes, Greece. Dr. Jose Uriel, M.D., Ph.D. has worked at the Pasteur Institute and was research director of the prestigious CNRS in France. He also worked at the Laboratory of Immunology, NIH Bethesda, Maryland. He directed the Laboratory of Protein Chemistry at the French Research Cancer Institute of which he was later the director. He has received the prestigious Rosen award in cancer research and he is a laureate of the French National Academy of Medicine (Leon Berat prize). Dr. Uriel has published more than 220 scientific papers and written several chapters in books related to cancer research, cancer markers and the receptor for AFP (RECAF). His lecture for ISOBM 2005 is entitled: "The Physiological Role of AFP and its Cell Receptors" (RECAF).  Dr. Ricardo Moro, M.D., a founder of BioCurex was appointed President and CEO in May 2003. He discovered and pioneered the work on RECAF. He will lecture on the practical applications of RECAF for diagnosis and therapy. His presentation is entitled: "RECAF - a new tumor marker". Dr. Phil Gold, C.C., O.Q., M.D., Ph.D. attended McGill University where he obtained four degrees. His Ph.D. thesis title was "Carcinoembryonic Antigens (CEA) of the Human Digestive System" which, along with the description of alpha-fetoprotein (AFP), ushered in the modern era of human tumor marker research along with the diagnostic impact that this work has had over the past 35 years. The assay for CEA developed by Gold, together with PSA, have become the most used markers for human cancer diagnosis and monitoring worldwide. In recognition of his scientific contributions, Dr. Gold has been the recipient of many international awards and honors. He holds positions as physician-in-chief, Department of Medicine, The Montreal General Hospital; Douglas G. Cameron, professor of medicine, McGill University; professor, Departments of Physiology and Oncology, McGill University and the director of the McGill University Medical Clinic at The Montreal General Hospital. This year is the 40th anniversary for his discovery of CEA and the title of his ISOBM 2005 lecture is: "CEA - 40 years after" which will include a discussion on the future of cancer markers and RECAF. Dr. Moro stated: "I am thrilled at this opportunity, largely due to the considerable recognition by the congress organizers on Dr. Gold's life work and the importance of this new cancer marker. Oral presentations are prestigious and very coveted among scientists because they allow the address to a singular large audience. We anticipate a significant audience consisting of members of academia, who will likely be interested in collaborating with us, as well as representatives from corporations interested in doing business with BioCurex. This is the right path towards spreading the word on RECAF, engaging other scientists to work on it and trigger the interest of large biotech companies as we have done before." About ISOBM:  The International Society of Oncodevelopmental Biology and Medicine (ISOBM) originated in the early 1970's from the International Research Group for Carcinoembryonic Proteins. It is devoted to bridging the gap between basic science and clinical application. As such, the ISOBM provides a unique forum for discussion and development of novel approaches to clinical problems in cancer. As a society we aim to support good communication between scientific interests, clinicians and commercial groups during our annual meetings and through the ISOBM Antibody Workshops system. The ISOBM is one of the longest standing and best reputed forums for cancer markers in the world and it publishes the journal "Tumor Biology". For more information on the ISOBM, please visit www.isobm.org. The scientific program and other congress related information can be found at www.isobm2005.org. About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (BOCX), visit our website at www.biocurex.com. Note:  The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. Contact: Ricardo Moro BioCurex, Inc. Tel: (604) 207 9150     We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130   Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the company. Under SEC Rule 144, 570,000 shares of the 1 million newly issued restricted shares are now eligible for sale into the public market. TGR Group has submitted the approriate filings to sell the shares.  In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.